Cleveland Biolabs Inc. (CLBI), a company that has long seen the potential for additional applications for its acute radiation exposure drug, entolimod, is putting the TLR5 agonist at the center of Genome Protection Inc. (GPI), a new joint venture formed with Everon Biosciences Inc. to develop and commercialize drugs for anti-aging applications, including frailty. Initially funded through a $10.5 million equity financing with venture capital fund Norma Investments Ltd., GPI's portfolio also includes small-molecule and vaccine candidates from Everon intended to protect organisms from the accumulation of cells with damaged DNA that drives aging and multiple age-related diseases, including cancer.